Finally, AMPK contributed to the anti-leukemic activity of venetoclax, as AMPK depletion protected venetoclax-treated AML cells from early apoptosis, which correlated with an increased amount of multi-domain anti-apoptotic effectors Mcl-1 and BclxL. This evidence concerns the gene PRKAA2 and acute myeloid leukemia.